Synergy between glutamate modulation and anti-programmed cell death protein 1 immunotherapy for glioblastoma

Immune checkpoint inhibitors such as anti-programmed cell death protein 1 (anti-PD-1) have shown promise for the treatment of cancers such as melanoma, but results for glioblastoma (GBM) have been disappointing thus far. It has been suggested that GBM has multiple mechanisms of immunosuppression, in...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of neurosurgery 2022-02, Vol.136 (2), p.379-388
Hauptverfasser:	Medikonda, Ravi, Choi, John, Pant, Ayush, Saleh, Laura, Routkevitch, Denis, Tong, Luqing, Belcaid, Zineb, Kim, Young Hoon, Jackson, Christopher M, Jackson, Christina, Mathios, Dimitrios, Xia, Yuanxuan, Shah, Pavan P, Patel, Kisha, Kim, Timothy, Srivastava, Siddhartha, Huq, Sakibul, Ehresman, Jeff, Pennington, Zach, Tyler, Betty, Brem, Henry, Lim, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Brain Neoplasms - drug therapy Brain Neoplasms - metabolism Cell Line, Tumor Glioblastoma - drug therapy Glioblastoma - metabolism Glutamic Acid Humans Immunotherapy - methods Mice Mice, Inbred C57BL Tumor Microenvironment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!